• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Outlook Therapeutics® Announces Executive Leadership Transition

    12/3/24 4:30:00 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OTLK alert in real time by email

    ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO.

    "On behalf of our management team and board, I would like to thank Russ for his dedication and many contributions to the Company and wish him the best in his future endeavors," commented Randy Thurman, the Company's Executive Chairman. "We are pleased to have Larry lead Outlook Therapeutics during this transition period. We remain committed to our plans to resubmit the BLA for ONS-5010 in the first quarter of calendar 2025 and to begin sales of LYTENAVA™ in Europe in the first half of calendar 2025."

    Mr. Kenyon has served as the Company's Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics' board of directors since August 2018 and also served as the Company's President and CEO from August 2018 to July 2021.

    The Company has engaged an executive search firm to work with the board of directors to identify a permanent CEO.

    About Outlook Therapeutics, Inc.

    Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™ would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "continue," "expect," "may," "will," or "would" the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, plans for commercial launch of LYTENAVA™ in the UK and EU and timing thereof, Outlook Therapeutics' commercialization strategy, the therapeutic potential of LYTENAVA™ as a treatment of wet AMD, ONS-5010's potential as the first FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal indications, including wet AMD, in the United States, expectations concerning Outlook Therapeutics' ability to remediate or otherwise resolve deficiencies identified in the CRL issued by the FDA, including plans to resubmit the BLA for ONS-5010 and the timing thereof, expectations concerning decisions of regulatory bodies and the timing thereof, and other statements that are not historical fact. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing and commercializing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, including the risk that the data from the NORSE EIGHT trial does not support the resubmission or subsequent filing by the FDA of the ONS-5010 BLA, the content and timing of decisions by regulatory bodies, the sufficiency of Outlook Therapeutics' resources, as well as those risks detailed in Outlook Therapeutics' filings with the Securities and Exchange Commission (the SEC), including the Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the SEC on December 22, 2023, and future quarterly reports Outlook Therapeutics files with the SEC, which include uncertainty of market conditions and future impacts related to macroeconomic factors, including as a result of the ongoing overseas conflicts, high interest rates, inflation and potential future bank failures on the global business environment. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

    Investor Inquiries:

    Jenene Thomas

    Chief Executive Officer

    JTC Team, LLC

    T: 908.824.0775

    [email protected]



    Primary Logo

    Get the next $OTLK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • Who has recently left the position of President and CEO at Outlook Therapeutics?

      Russell Trenary has stepped down as President and CEO of Outlook Therapeutics, Inc., effective immediately.

    • Who will be handling the CEO position on an interim basis following Russell Trenary's departure?

      Lawrence Kenyon has been appointed as the Interim CEO of Outlook Therapeutics.

    • When is Outlook Therapeutics expecting to start sales of LYTENAVA™ in Europe?

      LYTENAVA™ (bevacizumab gamma) is set to begin sales in Europe in the first half of calendar 2025, after receiving regulatory approval earlier this year.

    • What are the upcoming regulatory plans regarding ONS-5010 for Outlook Therapeutics?

      Outlook Therapeutics plans to resubmit the Biologics License Application (BLA) for ONS-5010 in the first quarter of calendar 2025.

    • What steps is Outlook Therapeutics taking to find a new permanent CEO?

      The company has engaged an executive search firm to find a permanent replacement for the CEO position.

    Recent Analyst Ratings for
    $OTLK

    DatePrice TargetRatingAnalyst
    12/2/2024Buy → Neutral
    Chardan Capital Markets
    3/27/2024$50.00Neutral → Buy
    BTIG Research
    2/15/2024$3.00Neutral → Buy
    Chardan Capital Markets
    1/25/2024Neutral → Buy
    Guggenheim
    12/27/2023$5.00Equal Weight → Overweight
    CapitalOne
    8/31/2023$5.00 → $1.00Buy → Neutral
    H.C. Wainwright
    8/31/2023Buy → Neutral
    Chardan Capital Markets
    8/30/2023Overweight → Equal Weight
    CapitalOne
    More analyst ratings

    $OTLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

      Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

      7/1/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

      ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET. As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP – Head of Europe, will discuss the Company's commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will h

      6/18/25 9:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

      ISELIN, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the Scottish Medicines Consortium (SMC) acceptance of LYTENAVA™ (bevacizumab gamma) for use within NHS Scotland for the treatment of wet age-related macular degeneration (wet AMD). LYTENAVA™ (bevacizumab gamma) is the first and only licensed ophthalmic formulation of bevacizumab for use in treating wet AMD in adults in the United Kingdom (UK) and has an initial 10 years of market exclusivity from the date of initial marketing authorization from the Medicines and H

      6/10/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    SEC Filings

    See more
    • Outlook Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

      7/1/25 4:31:32 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Outlook Therapeutics, Inc. (0001649989) (Filer)

      6/2/25 5:00:35 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Outlook Therapeutics Inc.

      424B5 - Outlook Therapeutics, Inc. (0001649989) (Filer)

      5/23/25 4:36:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Kenyon Lawrence A bought $28,446 worth of shares (5,000 units at $5.69), increasing direct ownership by 529% to 5,946 units (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      9/30/24 4:53:23 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Syntone Ventures Llc bought 714,286 shares, increasing direct ownership by 72% to 1,705,438 units (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      4/17/24 8:21:17 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Haddadin Yezan Munther bought $22,242 worth of shares (1,882 units at $11.82), increasing direct ownership by 59% to 5,049 units (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      3/29/24 10:39:09 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Outlook Therapeutics downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Outlook Therapeutics from Buy to Neutral

      12/2/24 10:06:30 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics upgraded by BTIG Research with a new price target

      BTIG Research upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $50.00

      3/27/24 7:31:34 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics upgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets upgraded Outlook Therapeutics from Neutral to Buy and set a new price target of $3.00

      2/15/24 7:17:37 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Sukhtian Ghiath M. was granted 4,285,714 shares (SEC Form 4)

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      5/28/25 5:20:21 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Director Sukhtian Ghiath M. exercised 3,458,571 shares at a strike of $2.51 (SEC Form 4)

      4/A - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      3/12/25 8:56:07 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Sukhtian Faisal Ghiath

      4 - Outlook Therapeutics, Inc. (0001649989) (Issuer)

      2/6/25 4:40:17 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Leadership Updates

    Live Leadership Updates

    See more
    • Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

      Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob Jahr as Chief Executive Officer (CEO). Mr. Jahr has also been appointed to the Outlook Therapeutics Board of Directors. Lawrence A. Kenyon, who has served as Outlook Therapeutics' Chie

      7/1/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

      ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced Faisal G. Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Mr. Sukhtian will assume the role from Randy Thurman, who will remain on the Board as Lead Independent Director. "On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest

      1/31/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Announces Executive Leadership Transition

      ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of bevacizumab authorized for the treatment of wet age-related macular degeneration (wet AMD) in adults, today announced that Russell Trenary has stepped down as the Company's President and Chief Executive Officer (CEO), effective immediately. Lawrence Kenyon, Executive Vice President, Chief Financial Officer and member of the board of directors, has been appointed Interim CEO. "On behalf of our management team

      12/3/24 4:30:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Financials

    Live finance-specific insights

    See more
    • Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

      LYTENAVA™ (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the second quarter of fiscal year 2025 and provided a corporate update. "Outlook Therapeutics remains on track in 2025 to transform into a commercial-stage company with the planned upcoming commercial launch of LYTENAVA™ (bevaciz

      5/15/25 4:01:00 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

      ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025LYTENAVA™ (bevacizumab gamma) on track for first commercial launches in Germany and the United Kingdom (UK) planned for Q2 CY2025 ISELIN, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for the first quarter of fiscal year 2025 and provided a co

      2/14/25 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

      LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK); First commercial launch anticipated in H1 CY25Received NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced financial results for fisca

      12/27/24 8:05:00 AM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OTLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

      SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      11/14/24 4:55:26 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Outlook Therapeutics Inc.

      SC 13G/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      11/7/24 4:17:05 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Outlook Therapeutics Inc. (Amendment)

      SC 13D/A - Outlook Therapeutics, Inc. (0001649989) (Subject)

      4/17/24 9:38:26 PM ET
      $OTLK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care